SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Bio-Rad Laboratories, Inc. – ‘10-Q’ for 6/30/22 – ‘EX-31.1’

On:  Friday, 7/29/22, at 4:07pm ET   ·   For:  6/30/22   ·   Accession #:  12208-22-46   ·   File #:  1-07928

Previous ‘10-Q’:  ‘10-Q’ on 4/29/22 for 3/31/22   ·   Next:  ‘10-Q’ on 10/28/22 for 9/30/22   ·   Latest:  ‘10-Q’ on 10/27/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 7/29/22  Bio-Rad Laboratories, Inc.        10-Q        6/30/22   73:10M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        10-Q June 30, 2022                                  HTML   2.01M 
 2: EX-31.1     EX-31.1 CEO Section 302 Certification 6.30.22       HTML     25K 
 3: EX-31.2     EX-31.2 CFO Section 302 Certification 6.30.22       HTML     25K 
 4: EX-32.1     EX-32.1 CEO Section 906 Certification 6.30.22       HTML     22K 
 5: EX-32.2     EX-32.2 CFO Section 906 Certification 6.30.22       HTML     22K 
11: R1          Document and Entity Information                     HTML     75K 
12: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML    159K 
13: R3          Condensed Consolidated Balance Sheets               HTML     32K 
                Parenthetical                                                    
14: R4          Condensed Consolidated Statements of Income         HTML     97K 
                (Unaudited)                                                      
15: R5          Condensed Consolidated Statements of Comprehensive  HTML     49K 
                Income (Unaudited)                                               
16: R6          Condensed Consolidated Statements of Cash Flows     HTML     93K 
                (Unaudited)                                                      
17: R7          Condensed Consolidated Statements of Stockholders'  HTML     72K 
                Equity Statement                                                 
18: R8          1. Basis of Presentation and Use of Estimates       HTML     73K 
19: R9          2. Fair Value Measurements                          HTML    202K 
20: R10         3. Intangible Assets, Goodwill and Other            HTML     77K 
21: R11         4. Statement of Cash Flows, Supplemental            HTML     47K 
                Disclosures                                                      
22: R12         5. Long-Term Debt                                   HTML     32K 
23: R13         6. Accumulated Other Comprehensive Income 7.        HTML     61K 
                Accumulated Other Comprehensive Income (Notes)                   
24: R14         7. Earnings Per Share                               HTML     34K 
25: R15         8. Other Income and Expenses                        HTML     39K 
26: R16         9. Income Taxes                                     HTML     29K 
27: R17         10. Segment Information Segment Reporting           HTML     61K 
28: R18         11. Legal Proceedings                               HTML     23K 
29: R19         12. Restructuring Costs (Notes)                     HTML     35K 
30: R20         13. Leases (Notes)                                  HTML     95K 
31: R21         Subsequent Events                                   HTML     23K 
32: R22         1. Basis of Presentation and Use of Estimates       HTML     86K 
                Basis of Presentation and Use of Estimates                       
                (Policies)                                                       
33: R23         1. Basis of Presentation and Use of Estimates       HTML     55K 
                Basis of Presentation and Use of Estimates                       
                (Tables)                                                         
34: R24         2. Fair Value Measurements (Tables)                 HTML    269K 
35: R25         3. Intangible Assets, Goodwill and Other (Tables)   HTML     85K 
36: R26         4. Supplemental Cash Flow Information Cash Flow,    HTML     47K 
                Supplemental Disclosure - (Tables)                               
37: R27         5. Long-Term Debt (Tables)                          HTML     36K 
38: R28         6. Accumulated Other Comprehensive Income 6.        HTML     62K 
                Accumulated Other Comprehensive Income (Tables)                  
39: R29         7. Earnings Per Share (Tables)                      HTML     33K 
40: R30         8. Other Income and Expenses (Tables)               HTML     38K 
41: R31         10. Segment Information Segment Reporting (Tables)  HTML     50K 
42: R32         12. Restructuring Costs (Tables)                    HTML     34K 
43: R33         13. Leases (Tables)                                 HTML     95K 
44: R34         1. Basis of Presentation and Use of Estimates       HTML     75K 
                Organization, Consolidation and Presentation of                  
                Financial Statements (Details)                                   
45: R35         1. Basis of Presentation and Use of Estimates       HTML     27K 
                Warranty Rollforward (Details)                                   
46: R36         1. Basis of Presentation and Use of Estimates       HTML     30K 
                Accounts Receivables Allowance for Credit Loss                   
                (Details)                                                        
47: R37         1. Basis of Presentation and Use of Estimates       HTML     22K 
                (Details)                                                        
48: R38         2. Fair Value Measurements Fair Value Level Table   HTML    222K 
                (Details)                                                        
49: R39         2. Foreign Exchange Forward Contracts (Details)     HTML     30K 
50: R40         2. Available-for-Sale Investments (Details)         HTML     72K 
51: R41         2. Amortized Cost and Fair Value of Debt            HTML     42K 
                Securities (Details)                                             
52: R42         2. Fair Value Financial Instruments (Details)       HTML     31K 
53: R43         2. Fair Value Measurements (Details)                HTML     22K 
54: R44         3. Intangible Assets, Goodwill and Other (Details)  HTML     34K 
55: R45         3. Intangible Assets, Goodwill and Other            HTML     69K 
                Intangible Assets (Details)                                      
56: R46         4. Supplemental Cash Flow Information - (Details)   HTML     79K 
57: R47         5. Long-Term Debt (Details)                         HTML     63K 
58: R48         6. Accumulated Other Comprehensive Income 6.        HTML     67K 
                Accumulated Other Comprehensive Income (Details)                 
59: R49         7. Earnings Per Share (Details)                     HTML     29K 
60: R50         8. Other Income and Expenses (Details)              HTML     34K 
61: R51         9. Income Taxes (Details)                           HTML     25K 
62: R52         Segment Reporting (Details)                         HTML     37K 
63: R53         10. Segment Information Segment Profit              HTML     55K 
                Reconciliations (Details)                                        
64: R54         10. Segment Information Segment Asset               HTML     29K 
                Reconciliation (Details)                                         
65: R55         12. Restructuring Costs (Details)                   HTML     52K 
66: R56         13. Leases (Details)                                HTML    124K 
67: R57         Subsequent Events (Details)                         HTML     23K 
68: R58         14. Subsequent Events (Details)                     HTML     25K 
71: XML         IDEA XML File -- Filing Summary                      XML    129K 
69: XML         XBRL Instance -- bio-20220630_htm                    XML   3.31M 
70: EXCEL       IDEA Workbook of Financial Reports                  XLSX    145K 
 7: EX-101.CAL  XBRL Calculations -- bio-20220630_cal                XML    187K 
 8: EX-101.DEF  XBRL Definitions -- bio-20220630_def                 XML    898K 
 9: EX-101.LAB  XBRL Labels -- bio-20220630_lab                      XML   1.62M 
10: EX-101.PRE  XBRL Presentations -- bio-20220630_pre               XML   1.06M 
 6: EX-101.SCH  XBRL Schema -- bio-20220630                          XSD    123K 
72: JSON        XBRL Instance as JSON Data -- MetaLinks              440±   666K 
73: ZIP         XBRL Zipped Folder -- 0000012208-22-000046-xbrl      Zip    457K 


‘EX-31.1’   —   EX-31.1 CEO Section 302 Certification 6.30.22


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:July 29, 2022 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board,
   President and Chief Executive Officer



Dates Referenced Herein

This ‘10-Q’ Filing    Date    Other Filings
Filed on:7/29/22None on these Dates
For Period end:6/30/22
 List all Filings 
Top
Filing Submission 0000012208-22-000046   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 6, 5:24:49.1am ET